Abstract
Hypoxia/ischemia brain damage (HIBD) is one of the most common central nervous system insults in newborns. Brain repair following HIBD is closely associated with cellular processes such as cell survival, angiogenesis, and neurogenesis. In recent years, many studies have suggested that ginsenoside Rg1, one of the major active ingredients of ginseng, may increase neural viability, promote angiogenesis, and induce neurogenesis. However, there are few reports on roles of Rg1 in HIBD repair, and the mechanisms involved are unclear. Recently, a Chinese drug consisting of Rg1 has been shown to be a potential regulator of hypoxia-inducible factor-1α expression in HIBD. Since it has been shown that HIF-1α is a key transcription factor involved in the neuroprotective response to HIBD, it is possible that Rg1 could facilitate the process of brain repair, possibly modulating cell survival, angiogenesis, and neurogenesis after HIBD by targeting HIF-1α.
Keywords: Angiogenesis, cell survival, cellular signal pathway, ginsenoside Rg1, hypoxia inducible factor-1α, hypoxia/ischemia brain damage, neurogenesis
CNS & Neurological Disorders - Drug Targets
Title: Targeting Hypoxia Inducible Factor-1α: A Novel Mechanism of Ginsenoside Rg1 for Brain Repair after Hypoxia/Ischemia Brain Damage
Volume: 10 Issue: 2
Author(s): Binzhi Tang, Yi Qu, Dejian Wang and Dezhi Mu
Affiliation:
Keywords: Angiogenesis, cell survival, cellular signal pathway, ginsenoside Rg1, hypoxia inducible factor-1α, hypoxia/ischemia brain damage, neurogenesis
Abstract: Hypoxia/ischemia brain damage (HIBD) is one of the most common central nervous system insults in newborns. Brain repair following HIBD is closely associated with cellular processes such as cell survival, angiogenesis, and neurogenesis. In recent years, many studies have suggested that ginsenoside Rg1, one of the major active ingredients of ginseng, may increase neural viability, promote angiogenesis, and induce neurogenesis. However, there are few reports on roles of Rg1 in HIBD repair, and the mechanisms involved are unclear. Recently, a Chinese drug consisting of Rg1 has been shown to be a potential regulator of hypoxia-inducible factor-1α expression in HIBD. Since it has been shown that HIF-1α is a key transcription factor involved in the neuroprotective response to HIBD, it is possible that Rg1 could facilitate the process of brain repair, possibly modulating cell survival, angiogenesis, and neurogenesis after HIBD by targeting HIF-1α.
Export Options
About this article
Cite this article as:
Tang Binzhi, Qu Yi, Wang Dejian and Mu Dezhi, Targeting Hypoxia Inducible Factor-1α: A Novel Mechanism of Ginsenoside Rg1 for Brain Repair after Hypoxia/Ischemia Brain Damage, CNS & Neurological Disorders - Drug Targets 2011; 10 (2) . https://dx.doi.org/10.2174/187152711794480456
DOI https://dx.doi.org/10.2174/187152711794480456 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Therapeutic Moderate Hypothermia and Fever
Current Pharmaceutical Design Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Age Matching Animal Models to Humans - Theoretical Considerations
Current Drug Discovery Technologies Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology Brain local and regional neuroglial alterations in Alzheimer´s Disease: cell types, responses and implications.
Current Alzheimer Research From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders Role of Connexins and Pannexins in Ischemic Stroke
Current Medicinal Chemistry Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Bridge Between Neuroimmunity and Traumatic Brain Injury
Current Pharmaceutical Design Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Synergistic Growth Inhibitory Effects of Eryngium kotschyi Extracts with Conventional Cytotoxic Agents: Cisplatin and Doxorubicin against Human Endometrium Cancer Cells
Current Pharmaceutical Biotechnology Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Conference Report: 181<sup>st</sup> Annual Meeting of the American Association for the Advancement of Science (AAAS), San Jose Convention Center, San Jose, CA, USA February 12-16, 2015
CNS & Neurological Disorders - Drug Targets